Summary
Global Macular Degeneration Treatment Market was valued at USD 13.10 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.30% through 2029. Macular degeneration, a common eye condition predominantly affecting individuals aged 50 and older, poses a significant risk to vision. It involves the deterioration of the macula, the central part of the retina crucial for sharp, central vision. For instance, a research study published in the SN Comprehensive Clinical Medicine Journal in October 2020 examined clinic visits for intravitreal injections (IVI) used in macular degeneration treatment over a one-month period from March 15 to April 14, 2020, comparing them with the same timeframe over the previous four years. The study found a decrease in clinic visits for IVI compared to the corresponding four-week period in the previous years. During a four-week period amid the COVID-19 outbreak in 2020, 636 eyes received injections at the Retina Clinic, Israel, compared to 995 injections in 2019.
Nevertheless, the relaxation of regulations and the commencement of vaccination programs have prompted a rebound in the macular degeneration market. Key contributors to the growth of the macular degeneration treatment market include the escalating prevalence of retinal disorders, the rise in the elderly population, and heightened investments in research and development.
Key Market Drivers
Rising Aging Population Demographics
The burgeoning aging population worldwide is a key catalyst propelling the growth of the Global Macular Degeneration Treatment Market. As individuals age, the prevalence of macular degeneration, a degenerative eye condition, increases significantly. This demographic shift creates a substantial market demand for innovative and effective treatment solutions, driving investment and research in the field.
The rising incidence of age-related macular degeneration (AMD) fuels the demand for therapeutic interventions, such as pharmaceuticals and advanced medical technologies, to address the specific needs of the aging demographic. Additionally, the increasing awareness and proactive healthcare approaches among the elderly contribute to the market expansion. Pharmaceutical companies and healthcare providers are strategically positioning themselves to capitalize on this trend, developing and commercializing novel treatments to cater to the growing patient pool. Consequently, the Global Macular Degeneration Treatment Market is experiencing robust growth as a direct result of the aging population demographics, presenting lucrative opportunities for stakeholders in the healthcare sector. As the elderly population continues to grow, the market is poised for sustained expansion, making it a focal point for investors and businesses operating in the healthcare industry.
Growing Awareness and Screening Programs
The burgeoning growth of the Global Macular Degeneration Treatment Market is significantly propelled by the increasing awareness and proactive screening programs. Heightened public consciousness about the risks and symptoms of macular degeneration has led to a rise in early diagnosis, creating a surge in demand for effective treatment options. As individuals become more informed about the importance of regular eye check-ups, they are increasingly likely to seek medical attention for early detection of macular degeneration, fostering a robust market ecosystem.
Government initiatives and private sector organizations are actively contributing to the expansion of screening programs, amplifying the market reach. This concerted effort to identify cases at an early stage not only benefits individuals by facilitating timely treatment but also acts as a driving force behind the growth of the entire treatment market. The collaboration between healthcare providers, pharmaceutical companies, and advocacy groups in promoting awareness campaigns plays a pivotal role. This synergistic approach not only educates the public but also creates a conducive environment for market players to innovate and invest in advanced treatment solutions. In essence, the intersection of growing awareness and widespread screening programs acts as a catalyst, fostering sustained growth in the Global Macular Degeneration Treatment Market.
Government Initiatives and Funding Support
The growth trajectory of the Global Macular Degeneration Treatment Market is substantially influenced by government initiatives and funding support. Governments worldwide are recognizing the escalating impact of macular degeneration on public health, prompting them to implement strategic measures that drive advancements in treatment solutions. Financial support from governmental bodies bolsters research and development efforts, fostering innovation in pharmaceuticals and medical technologies specifically tailored for macular degeneration.
Government initiatives often include funding programs, grants, and collaborative partnerships with the private sector to accelerate the development of effective treatments. This financial backing not only incentivizes pharmaceutical companies but also attracts investment in clinical trials and technological advancements, creating a conducive environment for market growth. Regulatory support in the form of expedited approval processes for breakthrough treatments encourages market players to invest in the development of novel therapies. Government-driven policies that prioritize the accessibility of these treatments contribute to the expansion of the market by ensuring widespread availability and affordability. In essence, the symbiotic relationship between government initiatives and funding support creates a dynamic ecosystem that propels the Global Macular Degeneration Treatment Market forward, addressing both medical needs and economic opportunities.
Key Market Challenges
Limited Awareness in Underserved Regions
The limited awareness in underserved regions poses a significant obstacle to the growth of the Global Macular Degeneration Treatment Market. In these areas, a lack of knowledge about macular degeneration leads to delayed diagnosis and treatment initiation. The absence of awareness campaigns and educational initiatives results in a substantial portion of the population remaining uninformed about the condition, hindering the timely identification of symptoms and the adoption of preventive measures. The restricted awareness also contributes to a lower demand for macular degeneration treatments in these regions, limiting market potential. Pharmaceutical companies and healthcare providers may be hesitant to invest in marketing and distribution efforts in areas where there is insufficient understanding of the disease. This lack of market demand, coupled with logistical challenges in reaching underserved regions, creates a barrier for companies aiming to expand their presence and sales in these areas. Addressing the awareness gap in underserved regions requires collaborative efforts between governments, non-profit organizations, and private sector stakeholders. By implementing targeted educational campaigns and increasing accessibility to healthcare services, the Global Macular Degeneration Treatment Market can overcome this challenge, ensuring that individuals in underserved regions have better access to information and timely treatment options.
Resistance to Adopt New Therapies
Resistance to adopt new therapies emerges as a substantial impediment to the growth of the Global Macular Degeneration Treatment Market. In certain segments of the population, there exists a reluctance to embrace innovative treatment options, often rooted in longstanding therapeutic traditions or skepticism towards novel approaches. This resistance poses a challenge for pharmaceutical companies seeking widespread adoption of advanced macular degeneration treatments. Physicians and patients may exhibit a conservative approach, favoring familiar or established treatments over newer, potentially more effective options. Overcoming this resistance necessitates robust efforts in educating healthcare professionals and the public about the benefits and advancements associated with novel therapies. Marketing strategies that address concerns, highlight efficacy, and emphasize safety profiles become crucial in changing perceptions and fostering acceptance.
Moreover, economic considerations and reimbursement policies may contribute to resistance, as patients and healthcare providers may be hesitant to navigate the financial implications of adopting new therapies. Clear communication on cost-effectiveness, long-term benefits, and potential improvements in patient outcomes becomes pivotal in overcoming resistance barriers. Strategic communication, targeted education, and aligning economic incentives are essential components in mitigating the resistance to adopting new therapies, thereby facilitating the growth of the Global Macular Degeneration Treatment Market.
Key Market Trends
Advancements in Gene Therapies
Advancements in gene therapies emerge as a pivotal driver propelling the growth of the Global Macular Degeneration Treatment Market. Innovative gene therapies hold the potential to revolutionize the landscape of macular degeneration treatment by addressing the underlying genetic factors contributing to the condition. These therapies, designed to target specific genetic mutations associated with macular degeneration, represent a paradigm shift in the approach to treatment. The development of gene therapies introduces a new frontier of precision medicine, offering tailored solutions that aim to modify or replace faulty genes contributing to the progression of macular degeneration. This approach not only enhances treatment efficacy but also holds the promise of long-term therapeutic benefits, potentially reducing the need for frequent interventions. As pharmaceutical companies invest in research and development to bring gene therapies to market, this creates a dynamic environment for growth within the macular degeneration treatment sector. Additionally, regulatory bodies acknowledging the potential of gene therapies and expediting approval processes further catalyze market expansion.
Expanded Use of Artificial Intelligence (AI)
The expanded use of Artificial Intelligence (AI) is a catalyst propelling the growth of the Global Macular Degeneration Treatment Market. AI applications, particularly in diagnostics and personalized medicine, are revolutionizing the approach to macular degeneration treatment. AI-powered imaging analysis enables more accurate and timely detection of disease progression, facilitating early intervention and personalized treatment plans. In diagnostics, AI algorithms enhance the interpretation of complex imaging data, aiding healthcare professionals in identifying subtle changes indicative of macular degeneration. This heightened precision not only streamlines the diagnostic process but also contributes to more effective and tailored treatment strategies.
AI-driven drug discovery and development processes accelerate the identification of potential therapies, expediting the introduction of novel treatments to the market. Predictive analytics and machine learning algorithms also play a crucial role in optimizing patient outcomes by identifying trends, predicting responses to specific treatments, and facilitating personalized care plans. As the healthcare industry increasingly embraces AI technologies, the Global Macular Degeneration Treatment Market stands to benefit from improved diagnostic accuracy, streamlined drug development, and enhanced treatment personalization, fostering a climate of innovation and driving market growth. The integration of AI not only augments efficiency but also positions the market to address the evolving needs of patients and healthcare providers in the realm of macular degeneration treatment.
Segmental Insights
Type Insights
Based on the Type, the Wet Age-related Macular Degeneration segment is anticipated to witness substantial market growth throughout the forecast period. The growth of the Global Macular Degeneration Treatment Market is significantly propelled by the prevalence of Wet Age-related Macular Degeneration (wet AMD), a driving force in the demand for advanced treatments. Wet AMD, characterized by abnormal blood vessel growth in the retina, poses a severe threat to vision and necessitates prompt and targeted intervention. The urgency associated with wet AMD treatment creates a substantial market demand for innovative pharmaceuticals and therapies. Pharmaceutical companies are investing heavily in research and development to introduce novel drugs and therapies specifically designed to address the complexities of wet AMD. The introduction of anti-VEGF (Vascular Endothelial Growth Factor) drugs, which inhibit the abnormal blood vessel growth, has emerged as a breakthrough in wet AMD treatment. As the aging population grows globally, the incidence of wet AMD is on the rise, further fuelling market expansion. The competitive landscape of the Global Macular Degeneration Treatment Market is shaped by the race among pharmaceutical firms to develop effective and efficient treatments for wet AMD, driving innovation, investment, and ultimately fostering sustained growth in the market. The focus on wet AMD underscores the market's responsiveness to evolving healthcare needs associated with age-related macular degeneration.
Treatment Type Insights
Based on the Treatment Type drug treatment type segment, the Biopharmaceutical Companies segment has been the dominant force in the market. The growth of the Global Macular Degeneration Treatment Market is significantly influenced by the evolution and diversification of drug treatment types. Pharmaceutical advancements play a pivotal role in shaping the market landscape, with continuous innovation in drug therapies driving sustained growth. Notably, the introduction and refinement of anti-VEGF (Vascular Endothelial Growth Factor) drugs have revolutionized macular degeneration treatment, particularly in addressing the wet form of the disease. These drugs, administered through injections, effectively inhibit abnormal blood vessel growth in the retina, representing a paradigm shift in treatment strategies. The competitive dynamics of the market are characterized by pharmaceutical companies striving to develop and commercialize more efficacious, convenient, and patient-friendly drug treatments. As the aging global population increases, the demand for effective drug treatments for macular degeneration rises, further propelling market expansion. The success and market adoption of novel drug treatments are contingent on factors such as efficacy, safety, and ease of administration. Ongoing research and development efforts focused on enhancing drug therapies underscore the dynamic nature of the Global Macular Degeneration Treatment Market, positioning it as a focal point for pharmaceutical innovation and investment in the evolving landscape of eye care.
Regional Insights
North America, specifically the Macular Degeneration Treatment Market, dominated the market in 2023, primarily due to North America is poised to be a key driver in the growth of the Global Macular Degeneration Treatment Market. The region exhibits a robust healthcare infrastructure, coupled with a high prevalence of age-related macular degeneration (AMD) within its aging population. The significant healthcare expenditures and advanced medical research capabilities in North America create an environment conducive to the development and adoption of cutting-edge macular degeneration treatments. Moreover, the region's proactive regulatory framework and well-established reimbursement mechanisms facilitate the swift approval and accessibility of innovative therapies. Leading pharmaceutical companies headquartered in North America are at the forefront of research and development, investing heavily in novel treatments, including gene therapies and advanced pharmaceuticals, thus influencing the global market landscape. The region's growing focus on precision medicine and personalized healthcare further supports the tailoring of macular degeneration treatments to individual patient needs. With a large patient pool, favorable regulatory conditions, and a commitment to medical innovation, North America is set to drive substantial growth in the Global Macular Degeneration Treatment Market, positioning it as a pivotal player in shaping the future of macular degeneration therapeutics.
Key Market Players
F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
PanOptica Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Aerie Pharmaceutical Inc.
REGENXBIO Inc.
Bayer AG
Lineage Cell Therapeutics Inc
Report Scope:
In this report, Global Macular Degeneration Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Macular Degeneration Treatment Market,By Type:
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
Macular Degeneration Treatment Market,By Stage of Disease:
Early-stage AMD
Intermediate AMD
Late-stage AMD
Macular Degeneration Treatment Market,By Treatment Type:
Drug
Devices
Surgery
Macular Degeneration Treatment Market,By Sales Channel:
Ambulatory Surgical Centers
Hospitals
Other
Macular Degeneration Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Macular Degeneration Treatment Market.
Available Customizations:
Global Macular Degeneration Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
·Detailed analysis and profiling of additional market players (up to five).
ページTOPに戻る
Table of Contents
1.Product Overview
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.Research Methodology
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations
3.Executive Summary
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.Voice of Customer
5.GlobalMacular Degeneration Treatment MarketOutlook
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
5.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
5.2.3.By Treatment Type (Drug,Devices,Surgery)
5.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
5.2.5.By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
5.2.6.By Company (2023)
5.3.Market Map
5.3.1 By Type
5.3.2 By Stage of Disease
5.3.3 By Treatment Type
5.3.4 By Sales Channel
5.3.5 By Region
6.North America Macular Degeneration Treatment Market Outlook
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
6.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
6.2.3.By Treatment Type (Drug,Devices,Surgery)
6.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
6.2.5.By Country
6.3.North America: Country Analysis
6.3.1.United States Macular Degeneration Treatment Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Type
6.3.1.2.2.By Stage of Disease
6.3.1.2.3.By Treatment Type
6.3.1.2.4.By Sales Channel
6.3.2.Canada Macular Degeneration Treatment Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Type
6.3.2.2.2.By Stage of Disease
6.3.2.2.3.By Treatment Type
6.3.2.2.4.By Sales Channel
6.3.3.Mexico Macular Degeneration Treatment Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Type
6.3.3.2.2.By Stage of Disease
6.3.3.2.3.By Treatment Type
6.3.3.2.4.By Sales Channel
7.Europe Macular Degeneration Treatment Market Outlook
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
7.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
7.2.3.By Treatment Type (Drug,Devices,Surgery)
7.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
7.2.5.By Country
7.3.Europe: Country Analysis
7.3.1.France Macular Degeneration Treatment Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Type
7.3.1.2.2.By Stage of Disease
7.3.1.2.3.By Treatment Type
7.3.1.2.4.By Sales Channel
7.3.2.Germany Macular Degeneration Treatment Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Type
7.3.2.2.2.By Stage of Disease
7.3.2.2.3.By Treatment Type
7.3.2.2.4.By Sales Channel
7.3.3.United Kingdom Macular Degeneration Treatment Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecast
7.3.3.2.1.By Type
7.3.3.2.2.By Stage of Disease
7.3.3.2.3.By Treatment Type
7.3.3.2.4.By Sales Channel
7.3.4.Italy Macular Degeneration Treatment Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Type
7.3.4.2.2.By Stage of Disease
7.3.4.2.3.By Treatment Type
7.3.4.2.4.By Sales Channel
7.3.5.Spain Macular Degeneration Treatment Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Type
7.3.5.2.2.By Stage of Disease
7.3.5.2.3.By Treatment Type
7.3.5.2.4.By Sales Channel
8.Asia-Pacific Macular Degeneration Treatment Market Outlook
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
8.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
8.2.3.By Treatment Type (Drug,Devices,Surgery)
8.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
8.2.5.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.China Macular Degeneration Treatment Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Type
8.3.1.2.2.By Stage of Disease
8.3.1.2.3.By Treatment Type
8.3.1.2.4.By Sales Channel
8.3.2.India Macular Degeneration Treatment Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Type
8.3.2.2.2.By Stage of Disease
8.3.2.2.3.By Treatment Type
8.3.2.2.4.By Sales Channel
8.3.3.Japan Macular Degeneration Treatment Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Type
8.3.3.2.2.By Stage of Disease
8.3.3.2.3.By Treatment Type
8.3.3.2.4.By Sales Channel
8.3.4.South Korea Macular Degeneration Treatment Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Type
8.3.4.2.2.By Stage of Disease
8.3.4.2.3.By Treatment Type
8.3.4.2.4.By Sales Channel
8.3.5.Australia Macular Degeneration Treatment Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Type
8.3.5.2.2.By Stage of Disease
8.3.5.2.3.By Treatment Type
8.3.5.2.4.By Sales Channel
9.South America Macular Degeneration Treatment Market Outlook
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
9.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
9.2.3.By Treatment Type (Drug,Devices,Surgery)
9.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
9.2.5.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Macular Degeneration Treatment Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Type
9.3.1.2.2.By Stage of Disease
9.3.1.2.3.By Treatment Type
9.3.1.2.4.By Sales Channel
9.3.2.Argentina Macular Degeneration Treatment Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Type
9.3.2.2.2.By Stage of Disease
9.3.2.2.3.By Treatment Type
9.3.2.2.4.By Sales Channel
9.3.3.Colombia Macular Degeneration Treatment Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Type
9.3.3.2.2.By Stage of Disease
9.3.3.2.3.By Treatment Type
9.3.3.2.4.By Sales Channel
10.Middle East and Africa Macular Degeneration Treatment Market Outlook
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
10.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
10.2.3.By Treatment Type (Drug,Devices,Surgery)
10.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
10.2.5.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Macular Degeneration Treatment Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Type
10.3.1.2.2.By Stage of Disease
10.3.1.2.3.By Treatment Type
10.3.1.2.4.By Sales Channel
10.3.2.Saudi Arabia Macular Degeneration Treatment Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Type
10.3.2.2.2.By Stage of Disease
10.3.2.2.3.By Treatment Type
10.3.2.2.4.By Sales Channel
10.3.3.UAE Macular Degeneration Treatment Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Type
10.3.3.2.2.By Stage of Disease
10.3.3.2.3.By Treatment Type
10.3.3.2.4.By Sales Channel
11.Market Dynamics
11.1.Drivers
11.2.Challenges
12.Market Trends Developments
12.1.Recent Development
12.2.Mergers Acquisitions
12.3.Product Launches
13.Global Macular Degeneration Treatment Market: SWOT Analysis
14.Porter’s Five Forces Analysis
14.1.Competition in the Industry
14.2.Potential of New Entrants
14.3.Power of Suppliers
14.4.Power of Customers
14.5.Threat of Substitute Products
15.Competitive Landscape
15.1.F Hoffmann-La Roche Ltd
15.1.1.Business Overview
15.1.2.Product Offerings
15.1.3.Recent Developments
15.1.4.Financials (As Reported)
15.1.5.Key Personnel
15.1.6.SWOT Analysis
15.2.Novartis AG
15.3.Pfizer Inc.
15.4.PanOptica Inc.
15.5.Bausch Health Companies Inc.
15.6.Regeneron Pharmaceuticals Inc.
15.7.Aerie Pharmaceutical Inc.
15.8.REGENXBIO Inc.
15.9.Bayer AG
15.10.Lineage Cell Therapeutics Inc.
16.Strategic Recommendations
17.About Us Disclaimer
